396 related articles for article (PubMed ID: 18465675)
1. Antibiotic development: a victim of market forces?
Tillotson GS
IDrugs; 2008 May; 11(5):340-6. PubMed ID: 18465675
[TBL] [Abstract][Full Text] [Related]
2. The antibiotic pipeline--challenges, costs, and values.
Wenzel RP
N Engl J Med; 2004 Aug; 351(6):523-6. PubMed ID: 15295041
[No Abstract] [Full Text] [Related]
3. Resistance to antibiotics: are we in the post-antibiotic era?
Alanis AJ
Arch Med Res; 2005; 36(6):697-705. PubMed ID: 16216651
[TBL] [Abstract][Full Text] [Related]
4. Drug companies snub antibiotics as pipeline threatens to run dry.
Clarke T
Nature; 2003 Sep; 425(6955):225. PubMed ID: 13679874
[No Abstract] [Full Text] [Related]
5. Antibacterial drug discovery: is it all downhill from here?
Projan SJ; Shlaes DM
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():18-22. PubMed ID: 15522036
[TBL] [Abstract][Full Text] [Related]
6. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
[TBL] [Abstract][Full Text] [Related]
7. The future of natural products as a source of new antibiotics.
Luzhetskyy A; Pelzer S; Bechthold A
Curr Opin Investig Drugs; 2007 Aug; 8(8):608-13. PubMed ID: 17668363
[TBL] [Abstract][Full Text] [Related]
8. Reducing antimicrobial resistance through appropriate antibiotic usage in Singapore.
Hsu LY; Kwa AL; Lye DC; Chlebicki MP; Tan TY; Ling ML; Wong SY; Goh LG
Singapore Med J; 2008 Oct; 49(10):749-55. PubMed ID: 18946605
[TBL] [Abstract][Full Text] [Related]
9. Innovation of novel antibiotics: an economic perspective.
McKellar MR; Fendrick AM
Clin Infect Dis; 2014 Oct; 59 Suppl 3():S104-7. PubMed ID: 25261536
[TBL] [Abstract][Full Text] [Related]
10. The state of innovation in drug development.
Kola I
Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
[TBL] [Abstract][Full Text] [Related]
11. Repairing the broken market for antibiotic innovation.
Outterson K; Powers JH; Daniel GW; McClellan MB
Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
[TBL] [Abstract][Full Text] [Related]
12. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
13. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
[TBL] [Abstract][Full Text] [Related]
15. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
Fitzgerald GA
Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
[TBL] [Abstract][Full Text] [Related]
16. Update on the antibacterial resistance crisis.
Croft AC; D'Antoni AV; Terzulli SL
Med Sci Monit; 2007 Jun; 13(6):RA103-18. PubMed ID: 17534243
[TBL] [Abstract][Full Text] [Related]
17. Compound scale-up at the discovery-development interface.
Nikitenko AA
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
[TBL] [Abstract][Full Text] [Related]
18. Monopoly pricing of an antibiotic subject to bacterial resistance.
Herrmann M
J Health Econ; 2010 Jan; 29(1):137-50. PubMed ID: 20015559
[TBL] [Abstract][Full Text] [Related]
19. Antibiotics at the crossroads.
Nathan C
Nature; 2004 Oct; 431(7011):899-902. PubMed ID: 15496893
[No Abstract] [Full Text] [Related]
20. Antibiotics: a shot in the arm.
Leeb M
Nature; 2004 Oct; 431(7011):892-3. PubMed ID: 15496888
[No Abstract] [Full Text] [Related]
[Next] [New Search]
